It wasn't perfect, but after the last couple of years we've had, investors should be happy to take it.
Yesterday Ironwood Pharmaceuticals
The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market. Last year we had Bristol-Myers Squibb
Ironwood has one phase 3 compound, linaclotide, which treats chronic constipation. The drug has already passed two phase 3 trials and data from one more is expected in the second half of the year. Ironwood has a 50/50 partnership with Forest Labs
Finding the next Amgen
Is Ironwood worth the risk? Head over to Motley Fool CAPS and tell us what you think by giving the stock an outperform or underperform rating.
More from The Motley Fool
The Roth IRA Trick Congress Is Planning to Take Away
A key strategy could disappear under tax reform.
What's Going on With Amazon Web Services in China?
In spite of regulatory burdens, Amazon is doubling down in China.
Micron Technology’s Q1 Earnings: What to Watch
Micron stock has cratered, but a turnaround could be around the corner.